APR 21, 2020 1:32 AM PDT

Classic Chemotherapeutic Repurposed for Treating Leukemia

WRITTEN BY: Nouran Amin

 

Researchers were seeking a promising new strategy to challenge drug resistance in leukemia. They found that targeted low doses of the widely-used chemotherapy drug doxorubicin is effective in overcoming resistance by leukemic cells.

"In low doses, doxorubicin actually stimulated the immune system, in contrast with the typical clinical doses, which were immunosuppressive, killing healthy immune cells indiscriminately," says John M. Perry, PhD, a researcher with the Children's Mercy Research Institute at Children's Mercy. He completed his postdoctoral work at Stowers and is first author of the report.

Doxorubicin is an anthracycline antibiotic that inhibits the interaction of two molecular pathways— Wnt/beta-catenin and PI3K/Akt--that promote tumor growth.

"Our idea was to find a drug with the goal of blocking the interaction between Wnt/beta-catenin and PI3K/Akt and reduce the toxicity," says Stowers Institute Investigator Linheng Li, PhD.

Findings were published in the journal Nature Cell Biology.

"We found that mice receiving patient sample transplants with therapy-resistant leukemia stem cells rapidly developed leukemia, but low-dose doxorubicin treatment improved survival by reducing leukemia stem cells," Perry says. "However, mice receiving patient sample transplants that did not contain therapy-resistant leukemia stem cells did not respond to low-dose doxorubicin treatment. These results showed that chemoresistant leukemia stem cells from patients could be functionally reduced with low-dose doxorubicin treatment, at least in an in vivo animal model assay."

Learn more about overcoming drug resistance in leukemia:

"The research holds promise as a more effective strategy to overcome cancer therapy resistance and immune escape that can be used in combination with other cancer therapies including chemotherapy, radiation, and immunotherapy for patients with leukemia and other types of cancer," Li says.

Source: Science Daily

 

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 17, 2021
Drug Discovery & Development
Facebook AI May Speed up Cancer Drug Discovery
APR 17, 2021
Facebook AI May Speed up Cancer Drug Discovery
Facebook has claimed that its new artificial intelligence, known as 'Compositional Perturbation Autoencoder' (CP ...
MAY 06, 2021
Drug Discovery & Development
Tweaked Version of Ketamine Could Solve the Opioid Crisis
MAY 06, 2021
Tweaked Version of Ketamine Could Solve the Opioid Crisis
Medications that manage post-operative pain are some of the main entry points to opioid addiction and overdose in the US ...
JUN 21, 2021
Cardiology
Researchers Find Evidence That Gut Microbes Affect Stroke Severity
JUN 21, 2021
Researchers Find Evidence That Gut Microbes Affect Stroke Severity
Research has indicated that there is a connection between gut microbes and heart health. Now scientists are revealing so ...
JUN 21, 2021
Cannabis Sciences
Cannabis Capsule Combo Could Treat Alzheimer's
JUN 21, 2021
Cannabis Capsule Combo Could Treat Alzheimer's
Researchers led by Curtin University in Australia have developed tiny cannabidiol (CBD) capsules that could one day be u ...
JUL 16, 2021
Drug Discovery & Development
Machine Learning Ranks Cancer Drugs by Efficacy
JUL 16, 2021
Machine Learning Ranks Cancer Drugs by Efficacy
A machine learning algorithm developed by researchers at the Queen Mary University of London in the UK can rank cancer d ...
JUL 18, 2021
Drug Discovery & Development
COVID-19 Antibiotic No More Effective than Placebo
JUL 18, 2021
COVID-19 Antibiotic No More Effective than Placebo
Azithromycin, a broad-spectrum antibiotic commonly used to prevent symptoms of COVID-19 in non-hospitalized patients, do ...
Loading Comments...